A novel non-agonist c-Met antibody drug conjugate with superior potency over a c-Met tyrosine kinase inhibitor in c-Met amplified and non-amplified cancers

c-Met is a well-characterized oncogene that is associated with poor prognosis in many solid tumor types. While responses to c-Met inhibitors have been observed in clinical trials, activity appears to be limited to those with MET gene amplifications or mutations. We developed a c-Met targeted antibod...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Biol Ther
Hlavní autoři: Fujita, Ryo, Blot, Vincent, Wong, Eley, Stewart, Christine, Lieuw, Vincent, Richardson, Robyn, Banah, Ammar, Villicana, Jose, Timmer, Anjuli, Coronella, Julia, Newman, Roland, Gymnopoulos, Marco
Médium: Artigo
Jazyk:Inglês
Vydáno: Taylor & Francis 2020
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7515515/
https://ncbi.nlm.nih.gov/pubmed/32192391
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2020.1737490
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky